Effervescent enteric coated L-dopa formulation and method of using the same
US3961041A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 10, 1975 |
| Grant date | Jun 1, 1976 |
| Priority date | — |
| Expiry date | Apr 10, 1995 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Therapeutic levels of L-DOPA are achieved by orally administering a pharmaceutical effervescent-enteric coated tablet comprising: PA1 A. a member selected from the group consisting of L-DOPA or a derivative thereof capable of enzymatically cleaving and reverting to L-DOPA in vivo, PA1 B. a non-toxic pharmaceutically acceptable inert diluent, PA1 C. a non-toxic pharmaceutically acceptable carbon dioxide releasing agent, PA1 D. a non-toxic pharmaceutically acceptable effervescing agent, and PA1 E. a non-toxic pharmaceutically acceptable enteric coating. This composition is extremely useful in the treatment of Parkinsonism. When administered to warm-blooded animals (e.g., humans), superior therapeutic blood levels of L-DOPA are observed over that normally observed with conventional enteric coated formulations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.